GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
F

Firebrick Pharma FRE.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.03

0.00%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in AUD, from our data supplier.

FY2026

Revenue

A$106,029

FY2019FY2026

Net income

−A$3.1m

FY2019FY2026

Free cash flow

−A$2.6m

FY2019FY2026

Shareholders' equity

A$1.7m

FY2019FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
RevenueA$106,029A$293,422A$14,522A$830A$4,124A$422,000A$508,977—
Research and developmentA$549,253A$735,197A$1.9mA$4.1mA$2.2mA$1.1mA$1.6mA$1.1m
Operating income−A$3.1m−A$2.9m−A$3.9m−A$6.9m−A$3.8m−A$2.9m−A$2.0m−A$1.2m
Net income−A$3.1m−A$2.6m−A$1.2m−A$6.8m−A$3.8m−A$2.4m−A$1.5m−A$725,258
Diluted earnings per share-0.01-0.01-0.01-0.04-0.02-0.01-0.01-0.00

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assetsA$2.2mA$1.8mA$2.4mA$3.0mA$8.7mA$11.8mA$654,814A$1.2m
Cash and short-term investmentsA$1.3mA$983,350A$824,776A$2.4mA$7.1mA$11.2mA$92,704A$577,462
Total liabilitiesA$483,029A$271,276A$291,069A$506,443A$450,100A$214,800A$264,216A$97,611
Debt——————A$54,412A$54,412
Shareholders' equityA$1.7mA$1.6mA$2.1mA$2.5mA$8.3mA$11.6mA$390,598A$1.1m
Shares outstanding263m243m202m176m169m169m169m263m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−A$2.6m−A$1.8m−A$2.3m−A$5.8m−A$4.2m−A$1.9m−A$985,008−A$1.1m
Capital spending−A$5−A$82,979−A$134−A$1,616−A$32,542−A$16,067−A$16,067—
Free cash flow−A$2.6m−A$1.9m−A$2.3m−A$5.8m−A$4.2m−A$2.0m−A$1.0m−A$1.1m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024
RevenueA$42,762A$63,267A$318,440A$159,220A$197,068A$98,534A$934,178A$467,089
Operating income−A$1.8m−A$1.3m−A$1.0m−A$522,000−A$1.3m−A$657,751−A$145,948−A$72,974
Net income−A$1.8m−A$1.3m−A$1.2m−A$594,025−A$1.4m−A$723,189−A$277,446−A$138,723
Diluted earnings per share-0.01-0.01-0.00-0.00-0.01-0.00-0.00-0.00
Cash from operations−A$1.0m−A$1.0m−A$1.0m———−A$1.0m—
Total assetsA$2.2mA$2.3mA$1.8mA$1.8mA$1.8mA$1.8mA$2.4mA$2.4m
Cash and short-term investmentsA$1.3mA$1.4mA$983,350A$983,350A$911,201A$911,201A$824,776A$824,776
Shareholders' equityA$1.7mA$1.9mA$1.6mA$1.6mA$1.5mA$1.5mA$2.1mA$2.1m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue403.6%-24.1%—
Operating income-23.3%1.6%—
Net income-23.3%4.7%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-1494.0%-4040.2%-2784.3%—
Net margin-1426.4%-3296.9%-2367.7%—

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022
Price to earnings-2.4-4.9-10.6-1.3-1.9
Price to sales69.444.0———

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.